🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this Expanded Access Program (EAP) is to enable the use of 8...
Status
No Longer Available
Location
Arkansas Urology
Start Date
TBD
Trial ID
NCT06090331
Treatments Being Tested
The study is a phase 2, non-comparative and non-randomized, single arm, nat...
Status
Recruiting
Location
IRCCS Ospedale San Raffaele
Start Date
2026-02-25
Trial ID
NCT07171905
Treatments Being Tested
The purpose of this study is to identify changes in Carbonic Anhydrase IX (...
Status
Recruiting
Location
NYU Langone Health
Start Date
2025-09-15
Trial ID
NCT07179770
Treatments Being Tested
89Zr-TLX250 is a carbonic anydrase IX (CAIX)-targeted imaging agent that is...
Status
Completed
Location
Yokohama City University Hospital
Start Date
2020-08-01
Trial ID
NCT04496089
Treatments Being Tested
89Zr-TLX250 is under clinical development as a diagnostic agent targeting c...
Status
Recruiting
Location
Beijing Cancer Hospital
Start Date
2024-11-06
Trial ID
NCT06750419
Treatments Being Tested
This is an open label, single-arm, multicentre dose escalation (Part 1) and...
Status
Recruiting
Location
Macquarie University
Start Date
2023-05-23
Trial ID
NCT05868174
Treatments Being Tested
89Zr-TLX250 is under clinical development as a diagnostic agent targeting c...
Status
Completed
Location
City of Hope Comprehensive Cancer Center
Start Date
2019-08-15
Trial ID
NCT03849118
Treatments Being Tested
The study is designed to evaluate the safety, tolerability, radiation dosim...
Status
Completed
Location
Peking University Cancer Hospital & Institute
Start Date
2023-06-26
Trial ID
NCT05861778
Treatments Being Tested
This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb ...
Status
Recruiting
Location
UCLA / Jonsson Comprehensive Cancer Center
Start Date
2024-08-06
Trial ID
NCT06447103